NEW YORK (360Dx) – Marseille, France-based HalioDx said today that it has signed an exclusive agreement with Genecast for distribution of its Immunoscore colon-cancer assay in China.

As a result of the agreement, oncologists and patients in China will have access to the Immunoscore diagnostic assay, which is used to predict the risk of recurrence in patients with early-stage colon cancer, HalioDx said.

Financial and other terms of the agreement were not disclosed.